Joan How

874 total citations
39 papers, 543 citations indexed

About

Joan How is a scholar working on Genetics, Rheumatology and Hematology. According to data from OpenAlex, Joan How has authored 39 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Genetics, 21 papers in Rheumatology and 21 papers in Hematology. Recurrent topics in Joan How's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers), Eosinophilic Disorders and Syndromes (20 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Joan How is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers), Eosinophilic Disorders and Syndromes (20 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Joan How collaborates with scholars based in United States and Netherlands. Joan How's co-authors include Gabriela Hobbs, Ann Mullally, Stephen T. Oh, Amy Zhou, Jacqueline S. Garcia, Susan A. Fowler, Suzanne E. Schindler, Andrea Wang‐Gillam, Janelle Mann and Maria Q. Baggstrom and has published in prestigious journals such as Circulation, Blood and British Journal of Haematology.

In The Last Decade

Joan How

35 papers receiving 537 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joan How United States 14 270 199 186 168 84 39 543
Christina Fagerberg Denmark 17 285 1.1× 79 0.4× 114 0.6× 312 1.9× 100 1.2× 46 877
Mieke Aldenhoven Netherlands 9 104 0.4× 129 0.6× 90 0.5× 64 0.4× 36 0.4× 17 534
PD Kottaridis United Kingdom 13 103 0.4× 191 1.0× 43 0.2× 99 0.6× 88 1.0× 19 428
Susan Staba United States 5 169 0.6× 176 0.9× 42 0.2× 68 0.4× 27 0.3× 11 502
Annette Wundes United States 15 51 0.2× 148 0.7× 95 0.5× 97 0.6× 265 3.2× 35 813
Irum Khan United States 15 230 0.9× 307 1.5× 35 0.2× 289 1.7× 115 1.4× 47 805
Maria Bova Italy 17 693 2.6× 152 0.8× 293 1.6× 130 0.8× 73 0.9× 47 930
Luis A. Barrera Colombia 17 100 0.4× 53 0.3× 162 0.9× 191 1.1× 16 0.2× 27 830
Wen‐Chi Yang Taiwan 14 73 0.3× 143 0.7× 31 0.2× 165 1.0× 87 1.0× 39 508
Sita Bhella Canada 6 23 0.1× 124 0.6× 136 0.7× 151 0.9× 68 0.8× 44 442

Countries citing papers authored by Joan How

Since Specialization
Citations

This map shows the geographic impact of Joan How's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan How with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan How more than expected).

Fields of papers citing papers by Joan How

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan How. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan How. The network helps show where Joan How may publish in the future.

Co-authorship network of co-authors of Joan How

This figure shows the co-authorship network connecting the top 25 collaborators of Joan How. A scholar is included among the top collaborators of Joan How based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan How. Joan How is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Odenike, Olatoyosi, Anand Patel, Jeanne M. DeCara, et al.. (2026). Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. Blood Advances. 10(5). 1603–1613.
2.
How, Joan, Orly Leiva, Robert Redd, et al.. (2025). Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes. PubMed. 2(3). 100051–100051. 2 indexed citations
3.
Leiva, Orly, Anthony Kanelidis, Stanley Swat, et al.. (2025). Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms. JACC CardioOncology. 7(5). 538–553. 1 indexed citations
4.
Redd, Robert, Martin J. Aryee, Anna E. Marneth, et al.. (2024). Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Advances. 8(23). 6043–6054. 3 indexed citations
5.
How, Joan & Gabriela Hobbs. (2024). Pregnancy: MPN management before, during, and after pregnancy. Hematology. 2024(1). 541–546.
6.
Leiva, Orly, et al.. (2024). Myeloproliferative Neoplasms and Cardiovascular Disease: A Review. Current Treatment Options in Oncology. 25(10). 1257–1267. 3 indexed citations
7.
Leiva, Orly, Sophia Zhou, Joan How, Michelle Lee, & Gabriela Hobbs. (2024). Readmission outcomes after acute coronary syndrome among patients with myeloproliferative neoplasms. Atherosclerosis. 401. 119046–119046. 1 indexed citations
8.
Leiva, Orly, Joan How, Jeremy D. Grevet, Andrew M. Brunner, & Gabriela Hobbs. (2023). In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and atrial fibrillation: insights from the National Readmissions Database. Journal of Thrombosis and Thrombolysis. 57(2). 186–193. 3 indexed citations
9.
Leiva, Orly, Jose Alvarez‐Cardona, Joan How, Andrew M. Brunner, & Gabriela Hobbs. (2023). In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and heart failure: Insights from the National Readmissions Database. IJC Heart & Vasculature. 49. 101304–101304. 3 indexed citations
10.
11.
How, Joan, Orly Leiva, Anna E. Marneth, et al.. (2023). Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes. Blood. 142(Supplement 1). 4568–4568. 1 indexed citations
12.
How, Joan, et al.. (2021). Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants. Postgraduate Medicine. 133(5). 508–516. 3 indexed citations
13.
How, Joan, Siyang Ren, Donna Neuberg, et al.. (2021). Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. Blood Cancer Journal. 11(11). 176–176. 18 indexed citations
14.
How, Joan, Orly Leiva, Thomas Bogue, et al.. (2020). Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leukemia Research. 98. 106459–106459. 22 indexed citations
15.
How, Joan, Gabriela Hobbs, & Ann Mullally. (2019). Mutant calreticulin in myeloproliferative neoplasms. Blood. 134(25). 2242–2248. 55 indexed citations
16.
17.
18.
How, Joan, et al.. (2014). Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer. Histochemistry and Cell Biology. 142(2). 195–204. 8 indexed citations
19.
Sheridan, Margaret A., et al.. (2013). What are the links between maternal social status, hippocampal function, and HPA axis function in children?. Developmental Science. 16(5). 665–675. 45 indexed citations
20.
Hsu, Mei‐Yu, Sherry A. Rovinsky, Chiou-Yan Lai, et al.. (2008). Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation. Laboratory Investigation. 88(8). 842–855. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christina Fagerberg Breakdown of academic impact, for papers by Mieke Aldenhoven Breakdown of academic impact, for papers by PD Kottaridis Breakdown of academic impact, for papers by Susan Staba Breakdown of academic impact, for papers by Annette Wundes Breakdown of academic impact, for papers by Irum Khan Breakdown of academic impact, for papers by Maria Bova Breakdown of academic impact, for papers by Luis A. Barrera Breakdown of academic impact, for papers by Wen‐Chi Yang Breakdown of academic impact, for papers by Sita Bhella
Rankless by CCL
2026